|
Multiple Myeloma
|
0.020 |
Biomarker
|
disease |
BEFREE |
When the immunoglobulin-producing myeloma MPC11 is fused to a T lymphoma, Oct-2 production ceases, as does the expression of immunoglobulin, J chain, and several other B cell-specific gene products.
|
7600290 |
1994 |
|
Hodgkin Disease
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
Seven different cell lines derived from patients with Hodgkin's disease (HD), as well as primary H/Reed-Sternberg (RS) cells isolated from the pericardial fluid of a patient with HD, were compared with a number of hematopoietic and nonhematopoietic cell lines for the expression of Oct-2, a tissue-specific transcription factor normally restricted to B cells, and nuclear factor kappa B (NF-kappa B), an inducible transcription factor.
|
8639794 |
1996 |
|
Pericardial effusion
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Seven different cell lines derived from patients with Hodgkin's disease (HD), as well as primary H/Reed-Sternberg (RS) cells isolated from the pericardial fluid of a patient with HD, were compared with a number of hematopoietic and nonhematopoietic cell lines for the expression of Oct-2, a tissue-specific transcription factor normally restricted to B cells, and nuclear factor kappa B (NF-kappa B), an inducible transcription factor.
|
8639794 |
1996 |
|
Chronic Lymphocytic Leukemia
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Oct-2 gene was expressed in 82% of pre-B ALL and all B-CLL samples.
|
10905058 |
2000 |
|
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Oct-2 gene was expressed in 82% of pre-B ALL and all B-CLL samples.
|
10905058 |
2000 |
|
Precursor B-cell lymphoblastic leukemia
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Oct-2 gene was expressed in 82% of pre-B ALL and all B-CLL samples.
|
10905058 |
2000 |
|
B-CELL MALIGNANCY, LOW-GRADE
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Oct-2 gene was expressed in 82% of pre-B ALL and all B-CLL samples.
|
10905058 |
2000 |
|
Hodgkin Disease
|
0.040 |
Biomarker
|
disease |
BEFREE |
Down-regulation of BOB.1/OBF.1 and Oct2 in classical Hodgkin disease but not in lymphocyte predominant Hodgkin disease correlates with immunoglobulin transcription.
|
11154228 |
2001 |
|
Hodgkin Disease
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
Absence of Oct-2 and Bob-1 protein expression in primary H-RS cells was demonstrated by performing immunohistochemistry in 20 cases of classical Hodgkin's disease.
|
11280769 |
2001 |
|
Secondary malignant neoplasm of lymph node
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Furthermore, we identified several genes associated with lymph node metastasis including Oct-2 or histological types including Liver-Intestine Cadherin.
|
11782383 |
2002 |
|
Machado-Joseph Disease
|
0.010 |
Biomarker
|
disease |
BEFREE |
To further investigate the DAT activity in asymptomatic MJD (aMJD) gene carriers, we performed this prospective study using (99m)Tc-TRODAT-1 ([(99m)Tc][2[[2-[[[3-(4-chlorophenyl)-8-methyl-8-azabicyclo[3,2,1]oct-2-yl]-methyl](2-mercaptoethyl)amino]ethyl]amino]ethane-thiolato(3-)-N2,N2',S2,S2]oxo-[1R-(exo-exo)])) brain SPECT on 5 aMJD gene carriers, 10 age-matched MJD patients, and 10 age-matched healthy control subjects.
|
11850478 |
2002 |
|
Neoplasms
|
0.050 |
AlteredExpression
|
group |
BEFREE |
Mouse splenic and thymic lymphocytes and tumor tissues were analyzed for the expression of cytokines involved in inflammatory and immune responses, including tumor necrosis factor-alpha (TNF-alpha), interleukin 6 (IL-6), basic fibroblast growth factor (bFGF), and interleukin 12 (IL-12); for the activation of the transcription factors nuclear factor-kappaB (NF-kappaB) and the B cell-specific transcription factor Oct-2; and for the activation of the Src and Syk family kinases, components of B-cell receptor-induced signal-transduction pathways.
|
12072546 |
2002 |
|
Kidney Failure, Chronic
|
0.300 |
Biomarker
|
disease |
RGD |
Down-regulation of rat organic cation transporter rOCT2 by 5/6 nephrectomy.
|
12110012 |
2002 |
|
Chronic kidney disease stage 5
|
0.200 |
Biomarker
|
disease |
RGD |
Down-regulation of rat organic cation transporter rOCT2 by 5/6 nephrectomy.
|
12110012 |
2002 |
|
Diffuse Large B-Cell Lymphoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
In addition to their different clonal origin, Reed-Sternberg cells of Hodgkin's disease expressed a CD15+, CD20+ (rare cells), CD30+, Oct-2-, EBNA2-, LMP1+ phenotype, whereas anaplastic and Reed-Sternberg-like cells of diffuse large B-cell lymphoma were CD15-, CD20+, CD30+, Oct-2+, EBNA2+, and LMP1+.
|
12459631 |
2002 |
|
Adult Diffuse Large B-Cell Lymphoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
In addition to their different clonal origin, Reed-Sternberg cells of Hodgkin's disease expressed a CD15+, CD20+ (rare cells), CD30+, Oct-2-, EBNA2-, LMP1+ phenotype, whereas anaplastic and Reed-Sternberg-like cells of diffuse large B-cell lymphoma were CD15-, CD20+, CD30+, Oct-2+, EBNA2+, and LMP1+.
|
12459631 |
2002 |
|
B-Cell Lymphomas
|
0.040 |
AlteredExpression
|
group |
BEFREE |
However, it differs from other aggressive B-cell lymphomas in that it shows defective immunoglobulin production despite the expression of OCT-2, BOB.1, and PU.1 transcription factors and the lack of IgV(H) gene crippling mutations.
|
12507907 |
2003 |
|
Primary Effusion Lymphoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Ectopic expression of Oct-2 was able to fully restore PU.1 promoter activity in the PEL cell line BCBL-1, while PU.1 expression also reconstituted the activity of the lambdaB Ets-IRF site.
|
12592383 |
2003 |
|
Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
OCT-2 immunostaining was primarily restricted in normal lymphoid tissue to B cells, and was absent from most T-cell neoplasms.
|
12598320 |
2003 |
|
Classical Hodgkin's Lymphoma
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
It has previously been demonstrated that in cultured and in situ tumour cells of classical Hodgkin lymphoma (cHL), the immunoglobulin (Ig) promoter is inactive and its transcription factors Oct2 and/or BOB.1/OBF.1 are down-regulated.
|
14694522 |
2004 |
|
Adult Classical Hodgkin Lymphoma
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
It has previously been demonstrated that in cultured and in situ tumour cells of classical Hodgkin lymphoma (cHL), the immunoglobulin (Ig) promoter is inactive and its transcription factors Oct2 and/or BOB.1/OBF.1 are down-regulated.
|
14694522 |
2004 |
|
Diffuse Large B-Cell Lymphoma
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
Interestingly, there were several normal (eg germinal centre centroblasts and monocytoid B-cells) and malignant B-cell populations (eg a proportion of diffuse large B-cell lymphomas, DLBCLs) that were Ig-negative, despite their BOB.1/OBF.1 and Oct2 expression.
|
14694522 |
2004 |
|
B-Cell Lymphomas
|
0.040 |
AlteredExpression
|
group |
BEFREE |
However, it differs from other aggressive B-cell lymphomas in that it shows defective Ig production despite the expression of Oct-2, BOB.1, and PU.1 transcription factors, and a lack of IgV(H) gene crippling mutations.
|
15202521 |
2003 |
|
Diabetes Mellitus, Insulin-Dependent
|
0.020 |
Biomarker
|
disease |
BEFREE |
SLC22A2 and SLC22A3, two genes downstream of IGF2R that are imprinted in the mouse, showed no T1D association.
|
15531531 |
2004 |
|
Hyperuricemia
|
0.210 |
Biomarker
|
disease |
RGD |
Restored expression and activity of organic ion transporters rOAT1, rOAT3 and rOCT2 after hyperuricemia in the rat kidney.
|
15748710 |
2005 |